Skip to main content

Table 3 Data of patients completing Phase A of the trial

From: A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk

Parameters

Amlodipine 5 mg

Amlodipine 5 mg + ASA 100 mg

Baseline

3 months

Baseline

3 months

N

107

103

106

105

Sex (M/F)

54/53

51/52

53/53

53/52

Smokers (M/F)

12/10

11/10

12/9

12/8

SBP (mmHg)

156.4 ± 9.4

145.2 ± 8.4*

153.6 ± 9.0

146.1 ± 8.8*

DPB (mmHg)

95.9 ± 5.5

88.9 ± 4.1*

97.2 ± 5.9

87.7 ± 3.9*

Hs-CRP (mg/l)

2.1 ± 0.9

1.9 ± 0.7

1.9 ± 0.7

1.7 ± 0.5*^

ADN (μg/ml)

5.4 ± 1.2

5.6 ± 1.2

5.2 ± 1.0

6.2 ± 1.8*^

TNF-α (pg/ml)

2.4 ± 0.9

2.1 ± 0.7

2.3 ± 0.8

1.8 ± 0.5*^

IL-1β (pg/ml)

0.6 ± 0.5

0.5 ± 0.3

0.6 ± 0.5

0.3 ± 0.2*

MPO (ng/ml)

780.1 ± 220.3

740.3 ± 220.4

776.5 ± 218.5

702.7 ± 114.4*^

sCDL40 (pg/ml)

1254.4 ± 110.2

1231.3 ± 102.1

1260.7 ± 119.5

1064.5 ± 92.9*^

  1. Data are expressed as mean ± standard deviation.
  2. M males, F females, Hs-CRP high sensitivity C-reactive protein, ADN adiponectin, TNF-α tumor necrosis factor-α, IL-1β interleukin-1β, MPO myeloperoxidase, sCDL40 soluble CD40 ligand.
  3. * p < 0.05 vs baseline.
  4. ^ p < 0.05 vs amlodipine.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840